These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36374076)

  • 21. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
    Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea.
    Jeon J; Chin B
    J Korean Med Sci; 2022 Dec; 37(48):e352. PubMed ID: 36513054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India.
    Sinha S; N K; Suram VK; Chary SS; Naik S; Singh VB; Jain MK; Suthar CP; Borthakur S; Sawardekar V; Sk N; Reddy N; Talluri L; Thakur P; Reddy M; Panapakam M; Vattipalli R
    Cureus; 2022 Nov; 14(11):e31508. PubMed ID: 36532902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real life experience of molnupiravir as a treatment of SARS-CoV-2 infection in vaccinated and unvaccinated patients: a letter on its effectiveness at preventing hospitalization.
    Scioscia G; De Pace CC; Giganti G; Tondo P; Foschino Barbaro MP; Lacedonia D
    Ir J Med Sci; 2023 Oct; 192(5):2301-2303. PubMed ID: 36454535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
    De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
    J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.
    Rasmussen HB; Hansen PR
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
    Fischer W; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Loftis AJ; Alabanza P; Lipansky F; Painter WP
    medRxiv; 2021 Jun; ():. PubMed ID: 34159342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
    Hau RK; Wright SH; Cherrington NJ
    Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.